Jane Doe, et al., Plaintiffs, v. Joseph A. Ladapo, et al., Defendants.
This action presents a constitutional challenge to a Florida statute and rules that (1) prohibit transgender minors from receiving specific kinds of widely accepted medical care and (2) prohibit doctors from providing it. The treatments at issue are GnRH agonists, colloquially known as “puberty blockers,” and cross-sex hormones. This order grants a preliminary injunction.
"...the evidence on the other side—the evidence purportedly showing these treatments are ineffective or unsafe—is far weaker, not just of 'low' or 'very low' quality. Indeed, evidence suggesting these treatments are ineffective is nonexistent" (28).
"...the evidence supporting the treatments at issue is 'low' or 'very low' quality as those terms are used in the GRADE system" (28).
"...the fact that research-generated evidence supporting these treatments gets classified as 'low' or 'very low' quality on the GRADE scale does not mean the evidence is not persuasive, or that it is not the best available research-generated evidence on the question of how to treat gender dysphoria, or that medical treatments should not be provided consistent with the research results and clinical evidence" (28).
"It is commonplace for medical treatments to be provided even when supported only by research producing evidence classified as 'low' or 'very low' on this scale. The record includes unrebutted testimony that only about 13.5% of accepted medical treatments across all disciplines are supported by 'high' quality evidence on the GRADE scale. The defendants’ assertion that treatment should be banned based on the supporting research’s GRADE score is a misuse of the GRADE system" (29).
"There are also substantial benefits for the overwhelming majority of patients treated with GnRH agonists and cross-sex hormones. And there are risks attendant to not using these treatments, including the risk—in some instances, the near certainty—of anxiety and depression and even suicidal ideation. The challenged statute ignores the benefits that many patients realize from these treatments and the substantial risk posed by foregoing the treatments—the risk from failing to pursue what is, for many, the most effective available treatment of gender dysphoria" (31).
"...there are risks attendant to treatment with GnRH agonists and cross-sex hormones" (30).
"A[n] [unreplicated] study found that sheep who took GnRH agonists became worse at negotiating a maze, at least for a time. Another study showed a [not-statistically-significant but nonetheless-] concerning decrease in IQ among cisgender children treated for central precocious puberty with GnRH agonists" (30-31).
"There has long been, and still is, substantial bigotry directed at transgender individuals. Common experience confirms this, as does a Florida legislator’s remarkable reference to transgender witnesses at a committee hearing as 'mutants' and 'demons'" (33).
"...the many professional organizations that have endorsed treatment of gender dysphoria with GnRH agonists and hormones all have it wrong...the organizations were dominated by individuals who pursued good politics, not good medicine" (32).
"...it is fanciful to believe that all the many medical associations who have endorsed gender-affirming care, or who have spoken out or joined an amicus brief supporting the plaintiffs in this litigation, have so readily sold their patients down the river" (34).
"The overwhelming majority of doctors are dedicated professionals whose first goal is the safe and effective treatment of their patients. There is no reason to believe the doctors who adopted these standards were motivated by anything else" (34).
"...the treatments are available in appropriate circumstances in all the countries cited by the defendants, including Finland, Sweden, Norway, Great Britain, France, Australia, and New Zealand. Some or all of these insist on appropriate preconditions and allow care only in approved facilities—just as the Endocrine Society and WPATH standards insist on appropriate preconditions, and just as care in the United States is ordinarily provided through capable facilities" (35).
"...Florida now treats GnRH agonists and cross-sex hormones the same as European countries" (35).
"There is no evidence that this kind of care is routinely provided so badly that it should be banned outright" (36).
"...GnRH agonists and cross-sex hormones have sometimes been provided in Florida without the appropriate mental-health therapy and evaluation by a multidisciplinary team" (36).
"Regret is rare; indeed, the defendants have offered no evidence of any Florida resident who regrets being treated with GnRH agonists or cross-sex hormones. And the absence of objective tests to confirm gender dysphoria does not set it apart from many other mental-health conditions that are routinely diagnosed without objective tests and treated with powerful medications" (36-37).
"The difficulty diagnosing a patient calls for caution. It does not call for a one-size-fits-all refusal to provide widely accepted medical treatment" (37).
"...gender dysphoria is difficult to diagnose accurately—that gender identity can be fluid, that there is no objective test to confirm gender identity or gender dysphoria, and that patients treated with GnRH agonists or cross-sex hormones have sometimes come to regret it" (36).
"...if that [the use of GnRH agonists for extended time to reflect on gender identity] is a goal of treatment with GnRH agonists, it is certainly not the treatment’s primary goal" (38).
"...98% or more of adolescents treated with GnRH agonists progress to cross-sex hormones" (37).
"The high rate of progression from GnRH agonists to cross-sex hormones is not a reason to ban the treatments" (38).
"...GnRH agonists give a patient time to reflect on the patient’s gender identity and, if still convinced of a gender identity opposite the natal sex, to reflect on whether to go forward socially in the gender identity or natal sex" (37-38).
"That the FDA has not approved these drugs for treatment of gender dysphoria says precisely nothing about whether the drugs are safe and effective when used for that purpose. Off-label use of drugs is commonplace and widely accepted across the medical profession" (39).
"...while the Food and Drug Administration has approved GnRH agonists and the hormones at issue as safe and effective, the agency has not addressed their use to treat gender dysphoria" (38).
"That the FDA approved these drugs at all confirms that, at least for one use, they are safe and effective. This provides some support for the view that they are safe when properly administered and that they effectively produce the intended results—that GnRH agonists delay puberty and that testosterone and estrogen have masculinizing or feminizing effects as expected" (39).
The plaintiffs thus are entitled to a preliminary injunction of appropriate scope.
It is ordered:
So ordered on June 6, 2023.
The Act makes it a Class C felony for any “person” to “engage in or cause” the performance of certain medical treatments on any minor, “if the practice is performed for the purpose of attempting to alter the appearance of or affirm the minor's perception of his or her gender or sex, if that appearance or perception is inconsistent with the minor's sex as defined by [the] act.” This prohibition infringes upon the fundamental constitutional rights to parental autonomy and equal protection, violates the right to freedom of speech, is void for vagueness, and conflicts with the Affordable Care Act...Accordingly, and for the reasons set forth in the accompanying Memorandum of Law, Plaintiffs respectfully request that this Motion for a Temporary Restraining Order and/or Preliminary Injunction be granted without security.
"Parent Plaintiffs assert that the Act violates their constitutional right to direct the medical care of their children under the Fourteenth Amendment" (15).
"Defendants produce no credible evidence to show that transitioning medications are 'experimental.' While Defendants offer some evidence that transitioning medications pose certain risks, the uncontradicted record evidence is that at least twenty-two major medical associations in the United States endorse transitioning medications as well-established, evidence-based treatments for gender dysphoria in minors" (17).
"...the medical interventions Plaintiffs label 'essential' are experimental at best and outright harmful at worst" (102).
"...a right on the parent’s part could exist only if the child has a right to access experimental medical interventions. The parent’s parental-rights claim is 'derivative from, and therefore no stronger than' the child’s claim...Because neither parent nor child has the right to access particular medical procedures, a parent does not have the right to obtain that treatment for the child" (107).
"Against this backdrop, Parent Plaintiffs are substantially likely to show that they have a fundamental right to treat their children with transitioning medications subject to medically accepted standards and that the Act infringes on that right. The Act prevents Parent Plaintiffs from choosing that course of treatment for their children by criminalizing the use of transitioning medications to treat gender dysphoria in minors, even at the independent recommendation of a licensed pediatrician" (16-17).
"...for now at least, there is insufficient evidence to conclude that the benefits of the treatments outweigh the long-term risk they pose to vulnerable children" (102).
"Because there is no right of affirmative access to experimental gender-transition procedures in the first place, parents have no right to access experimental gender-transition procedures for their children" (103).
"Minor Plaintiffs claim that the Act discriminates against them based on their sex in violation of the Fourteenth Amendment" (21).
"The most obvious reason it will fail is that the Act does not discriminate based on sex or gender identity. No male or female can be subjected to the regulated experimental procedures. Nor are these discrete and defined procedures a proxy for transgender status: many transgender youth do not seek them, and youth who are not actually transgender have been subjected to them. Regardless, transgender status is not a suspect or quasi-suspect classification, particularly in the context of medical treatments that are tied to inherent biological realities. Absent a suspect classification, the Act need only pass rational basis review, and its classifications based on age and procedures advance the State’s compelling interest in protecting children from experimental treatments" (74).
"Governmental classification based on an individual’s gender nonconformity equates to a sex-based classification for purposes of the Equal Protection Clause. Glenn v. Brumby, 663 F.3d 1312, 1320 (11th Cir. 2011). Here, the Act prohibits transgender minors—and only transgender minors—from taking transitioning medications due to their gender nonconformity. See S.B. 184, ALA. 2022 REG. SESS. § 4(a)(1)–(3) (Ala. 2022). The Act therefore constitutes a sex-based classification for purposes of the Fourteenth Amendment" (22).
"Plaintiffs collectively claim that the Act is void for vagueness under the Fifth and Fourteenth Amendments because it does not sufficiently define 'what actions constitute ‘caus[ing]’ any of the proscribed activities upon a minor.” Compl. (Doc. 1) at 34–35" (24).
"Plaintiffs challenge only the word 'cause.' This challenge fails, for multiple reasons. First, a vagueness challenge may be raised only 'as a defense during an actual prosecution' or if an individual is being 'chilled from engaging in constitutional activity.' Bankshot Billiards, Inc. v. City of Ocala, 634 F.3d 1340, 1349–50 (11th Cir. 2011). As shown above, neither is true here" (112).
"Here, there is no question that Plaintiffs seek the right for their doctors to violate the law’s core prohibition on prescribing puberty suppressors and hormones for the purpose of changing gender" (112).
"Third, there is no impermissible vagueness in the term 'engage in or cause.' The same phrase litters American criminal codes—and has for centuries...The State is unaware of any decision suggesting that this term is so vague that every criminal statute using it is unconstitutional" (113).
"Plaintiffs collectively claim that the Act violates their First Amendment right to free speech by prohibiting 'any ‘person,’ including physicians, healthcare professionals, or even parents, from engaging in speech that would ‘cause’ a transgender minor to receive medical treatment for gender dysphoria'" (27).
"But on its face, the Act makes it a crime for any person to 'engage in or cause any of [several practices]' for the purpose of gender transitioning a minor. § 4(a). As Plaintiffs appear to concede (Br., Doc. 8 at 44), the only 'speech' that would be criminalized is speech that 'causes' a crime—for example, writing a prescription for an illegal use of a drug. See Act § 4(a)(1)-(3). Such speech has no First Amendment protection" (117).
"Again, this law prohibits certain practices. The only speech incidentally criminalized is speech that “causes”—as understood by well-established principles of causation—those criminal practices" (118).
"The Act prevents Parent Plaintiffs from treating their children with transitioning medications subject to medically accepted standards. S.B. 184, ALA. 2022 REG. SESS. § 4(a)(1)–(3) (Ala. 2022). The record shows that, without transitioning medications, Minor Plaintiffs will suffer severe medical harm, including anxiety, depression, eating disorders, substance abuse, self-harm, and suicidality. Tr. at 20, 167" (29-30).
"The problem with this argument is that it presumes gender-transition procedures would relieve any distress experienced by these children. But as shown exhaustively above, there is no evidence that this is true. For one thing, there is scientifically valid evidence suggesting just the opposite: that gender-transition procedures can lead to more significant distress and other mental-health problems. Supra at pp. 33-49. And because practitioners cannot distinguish those children whose transgender identity will desist from that those whose will persist, there is no way to assess the costs or supposed benefits of gender-transition procedures for any particular child" (137).
Accordingly, the final two factors favor injunctive relief.
DONE and ORDERED May 13, 2022.
Plaintiffs bring their claims under the Fourteenth Amendment’s Equal Protection and Due Process Clauses and the First Amendment.
"The Act also discriminates against transgender people. The law prohibits medical care that only transgender people choose to undergo, i.e, medical or surgical procedures related to gender transition" (65).
"...by banning gender-affirming care the Act advances the State’s important governmental interest of protecting children from experimental medical treatment and safeguarding medical ethics" (66).
"A minor assigned male at birth is not prohibited under Act 626 from receiving testosterone or surgical procedures 'such as subcutaneous mastectomy, voice surgery, liposuction, lipofilling, pectoral implants, or various aesthetic procedures' for the purpose of aligning himself with his biological sex. Act 626 does not prohibit a minor assigned female at birth from receiving estrogen or surgical procedures 'such as augmentation mammoplasty, facial feminization surgery, liposuction, lipofilling, voice surgery, thyroid cartilage reduction, gluteal augmentation, hair reconstruction or other aesthetic procedures' to enhance her appearance as long as the enhancements align with her biological sex. 'The biological sex of the minor patient is the basis on which the law distinguishes between those who may receive certain types of medical care and those who may not. The Act is therefore subject to heightened scrutiny. Id. at 670 (citing Heckler v. Mathews, 465 U.S. 728, 744 (1984))" (64-65).
"The evidence showed that based on the decades of clinical experience and scientific research, it is widely recognized in both the medical and mental health fields—including by major medical and mental health professional associations—that gender-affirming medical care can relieve the clinically significant distress associated with gender dysphoria in adolescents" (17-18).
"...the Act advances an interest in protecting children" (15).
"Dr. Turban testified about the sixteen studies conducted in multiple countries over the past twenty years that collectively show that use of pubertal suppression and gender-affirming hormones to treat adolescents with gender dysphoria improves patient health and prevents the worsening of distress upon the onset of puberty. (Id. ¶ 224.) He testified as well that the studies about the efficacy of hormone therapy show positive outcomes consistent with dozens of studies about the efficacy of such therapy to treat gender dysphoria in adults" (16-17).
"As stated, the evidence at trial showed the risks associated with gender-affirming care for adolescents are no greater than the risks associated with many other medical treatments that are not prohibited by Act 626. (Tr. 390, ECF No. 220 (Antommaria); Tr. 212:11-12, ECF No. 219 (Adkins)). The evidence showed that the banned treatments are effective to treat gender dysphoria and the benefits of the treatments greatly outweigh the risks" (71).
"...the risks of gender-affirming care banned by Act 626 substantially outweigh the benefits" (71).
"...the evidence proved that there is broad consensus in the field that once adolescents reach the early stages of puberty and experience gender dysphoria, it is very unlikely they will subsequently identify as cisgender or desist" (71).
"...minors with gender dysphoria will desist with age...there is a significant risk of harm to a minor who elects to undergo gender hormone therapy or surgery because they will eventually identify with their sex assigned at birth and regret the treatment they sought as a minor" (71).
"...there was no evidence that doctors in Arkansas negligently prescribe puberty blockers or cross-sex hormones to minors" (71).
"...the number of children identifying as transgender has increased in the last decade and researchers theorize that the increase could be due to mental illness, social encouragement, or abuse...the 'affirmative' model of treating gender dysphoria which utilizes puberty blockers, cross-sex hormones and surgeries allows doctors to 'throw caution out the window'" (72).
"There was no evidence presented that surgeons in Arkansas are performing gender transforming surgeries on minors much less performing surgeries on demand. In fact, the evidence confirmed that doctors in Arkansas do not perform gender transition surgeries on any person under the age of 18, the age which Act 626 targets" (72).
"...many doctors do not require mental health counseling before treatment and will let children get hormone therapy and permanently altering surgeries upon demand" (72).
"The Arkansas Medical Board is the best option for regulating the ethical considerations as well as the duties of the healthcare community in circumstances like the treatment of gender dysphoria. Plaintiff Parents’ testimony at trial confirmed that they have made the decision to get gender-affirming care for their children after discussions with and observations of their child, thorough research, counseling, and consultation with a doctor. They are acting in the best interest of their children. Act 626 would take away these parents’ fundamental right to provide healthcare for their children and give that right to the Arkansas Legislature" (76).
"The State has a compelling interest in 'safeguarding the physical and psychological well-being of a minor. . ..'" (75).
"Dr. Stambough claims that Act 626 restricts her freedom of speech by barring her from referring her patients to other healthcare professionals for gender transition treatment in violation of the First Amendment" (76).
"The State argues that the Act targets conduct, not communication, by healthcare professionals...writing an order, or 'referring,' a patient to another physician for gender transition procedures amounts to a treatment order. A treatment order is professional conduct subject to regulation by the State, even if it incidentally involves speech. The State argues that the Act’s purpose is to encourage speech in the form of psychotherapy for treatment of gender dysphoria" (77).
"As written, Act 626 clearly regulates speech and not conduct...It prevents doctors from informing their patients where gender transition treatment may be available. It effectively bans their ability to speak to patients about these treatments because the physician is not allowed to tell their patient where it is available" (78).
"...the State explains that it has a compelling interest in keeping children away from gender transition procedures because their efficacy and safety are doubtful" (78).
IT IS SO ORDERED this 20th day of June, 2023.
The State has a strong interest in enforcing democratically enacted laws. And Defendants have shown that there are important reasons underlying the State's regulation of gender transition procedures for minors. Still, Plaintiffs have carried their burden of showing some likelihood of success on their claims that S.E.A. 480 would violate their equal protection rights under the Fourteenth Amendment and free speech rights under the First Amendment. Under the evidence available at this preliminary stage, there is not a "close means–end fit" between the State's important reasons for regulating the provision of gender transition procedures to minors and S.E.A. 480's broad ban of those procedures. So, when the State's interests are weighed against the likelihood that Plaintiffs will be able to show that S.E.A. 480 would violate their constitutional rights and the risk of irreparable harm, Plaintiffs are entitled to a preliminary injunction.
"Plaintiffs argue that S.E.A. 480 'violates the equal protection rights of the plaintiff youth' because it impermissibly 'discriminates on the basis of both sex and transgender status'" (16).
"...S.E.A.480 instead makes reasonable classifications 'based on age, procedure, and condition—not sex or transgender status'" (16).
"Plaintiffs argue that heightened scrutiny applies here because, under S.E.A. 480, sex is the determining factor as to whether a treatment is prohibited" (16).
"...S.E.A. 480 draws distinctions based on other factors, such as medical condition and procedure, rather than based on sex" (16-17).
"In other words, the statute allows physicians and other practitioners to 'instill or create' characteristics 'resembl[ing]' female anatomical characteristics for females but not for males, and male anatomical characteristics for males but not for females. It's therefore impossible for a medical provider to know whether a treatment is prohibited without knowing the patient's sex. S.E.A. 480's prohibitions therefore 'cannot be stated without referencing sex'" (18).
"Defendants argue that S.E.A. 480's classifications are instead 'based on age, procedure, and medical condition' and 'encompass both sexes and all gender identities.'...because S.E.A. 480 prohibits all gender transition procedures, for both males and females, there's no sex-based classification" (18).
"Plaintiffs argue that S.E.A. 480 does not survive heightened scrutiny because there's no important government interest to justify prohibiting 'safe, effective, and medically necessary treatment for the health and well-being of adolescents suffering from gender dysphoria'" (21).
"Defendants contend that the prohibited treatments are unsafe and their effectiveness is unproven, so S.E.A. 480 is justified by the State's interests in protecting the wellbeing of minors and regulating the medical profession" (21).
"Defendants argue that this ban is justified because gender transition procedures 'subject vulnerable minors to unproven, harmful, and irreversible procedures'" (22).
"Plaintiffs Dr. Bast and Mosaic therefore challenge this provision as applied to its regulation of speech, arguing that it violates medical providers' First Amendment free speech rights because it prohibits making referrals for or providing information about gender transition procedures" (28).
"...§ 13(b) regulates speech only incidentally and is valid as part of a broader regulatory statute" (28).
"S.E.A. 480 § 13(b) therefore appears to burden speech 'on its face and in its practical operation' because 'aiding and abetting' directly prohibits referrals and collaboration among medical providers. Sorrell, 564 U.S. at 567. Moreover, the regulation triggers heightened scrutiny because it's 'directed at certain content and is aimed at particular speakers.' Id. at 567, 571. Section13(b) singles out medical providers and only one category of medical treatment—gender transition procedures" (29).
"Minor Plaintiffs argue that they would suffer irreparable harm if S.E.A.480 took effect because they would have to stop receiving puberty blockers or hormone therapy to treat the severe condition of gender dysphoria" (30).
"...psychotherapy is available as an alternative treatment" (30).
"...Defendants do not contest that gender dysphoria is a psychiatric diagnosis that requires 'clinically significant distress' to diagnose..." (30).
So Ordered. Date: 6/16/2023
This Court should follow the growing weight of authority and enter a preliminary injunction against enforcement of the Treatment Ban.
"By singling out treatments that target the defining feature of what it means to be transgender—that is, living consistent with a person’s gender identity rather than their birth sex—the Treatment Ban singles out transgender adolescents, depriving them of essential medical care because of their gender nonconformity, while permitting the same medications to be prescribed or administered for any other reason" (15).
"But nothing about the challenged provisions 'closes a door or denies opportunity' to just one of the sexes or 'create[s] or perpetuate[s] . . . the inferiority' of one of the sexes. The provisions apply equally to both sexes. Children of both sexes are prohibited from doing the same thing—taking off-label drugs to attempt to alter biological appearance inherent in sex. Since the challenged provisions apply to both sexes equally, it is impossible to conclude that they prefer one sex over the other, the necessary basis of a sex-based equal protection claim" (9).
"A law that 'prohibits transgender minors—and only transgender minors—from taking transitioning medications due to their gender nonconformity … constitutes a sex-based classification for purposes of the Fourteenth Amendment.' Eknes-Tucker, 603 F. Supp. 3d at 1147; accord Brandt, 47 F.4th at 670. Heightened scrutiny applies for this reason alone" (16).
"The Treatment Ban cannot withstand this test. First, denying transgender adolescents medically necessary treatments does not serve any important governmental objective. By prohibiting providers from prescribing or administering puberty delaying medications or hormone treatments to transgender adolescents, the Kentucky Legislature overrode generally accepted medical protocols for treatment of gender dysphoria. Based on medical research and clinical experience, groups such as the AMA, the AAP, the Endocrine Society, and the American Academy of Child and Adolescent Psychiatry all have determined that these medications are safe, effective, and necessary treatments for adolescents with gender dysphoria" (18-19).
"There is no fundamental right of a parent to obtain for a child whatever drugs the parent—much less, the child—desires, no matter what. And a law that classifies according to age and the non-FDA approved use of puberty blockers and cross-sex hormones for a particular purpose does not trigger heightened scrutiny" (5).
"...gender-dysphoric individuals are not a protected class entitled to heightened scrutiny" (13).
"Medical treatment for patients diagnosed with gender dysphoria has long been recognized as standard care by major medical associations" (19).
"In addition to lacking any basis in medical science, any purported claim that the Treatment Ban was enacted to protect health or safety is belied by the law’s express allowance of the same medications when prescribed or administered to non-transgender minors for any purpose other than treating gender dysphoria. That strongly suggests that the Kentucky Legislature was not genuinely motivated by any concern over whether these medications are safe for use by minors, but rather by disapproval of their use for transgender minors" (19).
"The risks associated with the prohibited medications are rare for transgender and non-transgender patients alike" (20).
"...there is no logical or rational connection between the Treatment Ban and any justifications that may be proffered by Defendants. Rather than protecting transgender minors from harm, the Treatment Ban deprives them of the only safe and effective treatments for their gender dysphoria, leaving them with no treatment for a serious medical condition that, when left untreated, predictably causes serious and irreparable harms. The Treatment Ban permits the same medications to be prescribed and administered to other minors, thereby belying any claim that the medications themselves are unsafe. And it imposes a sweeping and categorical ban, completely barring these treatments regardless of a minor’s individual medical circumstances or needs, and regardless of the severe and even life-threatening harm that may be caused for youth who have been benefitting from these medications and now must terminate them" (21).
"If the Court thinks intermediate scrutiny applies here, as long as the law serves 'important governmental objectives' and is 'substantially related to the achievement of those objectives,' it is constitutional. Virginia, 518 U.S. at 533 (citation omitted). Even under the strictest scrutiny, the challenged provisions need not be 'perfectly tailored.' Williams-Yulee v. Fla. Bar, 575 U.S. 433, 454 (2015). Whatever level of scrutiny is applied, the result remains the same—Sections 4(2)(a) and (b) of SB 150 are constitutional" (15).
"...the Treatment Ban deprives Parent Plaintiffs of their fundamental right to obtain medical treatment for their children that their children’s doctors have recommended, that has improved their children’s health and wellbeing, and that every major medical association has recognized as safe, effective, and necessary" (23).
"Their cursory argument is make-work. Sure, “parents’ substantive due process right ‘to make decisions concerning the care, custody, and control’ of their children includes the right to direct their children’s medical care.” Kanuszewski v. Mich. Dep’t of Health & Hum. Servs., 927 F.3d 396, 419 (6th Cir. 2019) (citation omitted). But this general right to make the ultimate decision from a list of available medical treatments does not translate into some sort of affirmative, limitless right to obtain whatever drugs the parent wants for his or her child, carte blanche" (5).
Dated: May 22, 2023
Pending before the Court is Plaintiffs’ motion for a preliminary injunction (Doc. No. 21, “Motion”), which is accompanied by a memorandum in support (Doc. No. 33).
"...SB 1 violates the Equal Protection Clause by discriminating against transgender minors on the basis of their sex and their membership in a quasi-suspect class. Not only does SB 1 fail to satisfy the heightened scrutiny applicable to such laws; it would fail even rational basis review" (9).
"The Act does not deny equal protection of the laws" (3).
"SB 1 discriminates on the basis of sex because the medical treatments available to a minor under SB 1 depend on the sex that minor was assigned at birth" (9).
"For example, under SB 1, if a minor was assigned female at birth, that minor cannot receive testosterone to treat gender dysphoria. By contrast, a non-transgender minor who was assigned male at birth can receive testosterone to treat low hormone production because the treatment is consistent with the sex the minor was assigned at birth" (10).
"Neither subsection triggers heightened scrutiny. Touching on biological sex is not sex discrimination. And, following Private Plaintiffs’ lead, the US ignores Sixth Circuit precedent that forecloses treating transgender status as a quasi-suspect class" (3).
"By limiting the receipt of specified forms of health care only to those minors whose gender identify differs from their sex assigned at birth, SB 1 imposes 'a broad and undifferentiated disability on a single named group.' Romer v. Evans, 517 U.S. 620, 632 (1996)" (22-23).
"The Act serves governmental interests that are not just important but also compelling. The United States, however, ignores the entire history of medical malfeasance that led to the Act. As a reminder, the Tennessee public learned in September 2022 that VUMC was engaged in a widespread and profit-motivated practice of prescribing hormones to and conducting surgeries on the State’s children" (10).
"The treatments prohibited by SB 1, which the statute inaccurately describes as 'experimental,' 'not supported by high-quality, long-term medical studies,' and 'harmful,' SB 1, § 68-33-101(b), are prohibited only for transgender minors, while the law permits the same treatments for non-transgender minors" (23).
"SB 1 will cause immense and irreparable physical and psychological harm to many transgender minors diagnosed with gender dysphoria by terminating their access to necessary medical treatment and impose harm on their parents and medical providers. As one district court explained, the following forms of irreparable harm can ensue: (1) transgender youths face 'high risk of gender dysphoria and lifelong physical and emotional pain,' (2) parents must choose between watching their children suffer or uprooting their family to move to another state, and (3) physicians must choose between violating the law and providing appropriate medical care" (24).
"Intervenor identifies no irreparable harm to the US itself. All of its asserted irreparable harms are nebulous ones to unspecified 'transgender youths,' parents who want this treatment for their children, and physicians who want to provide the prohibited treatments. Mem.24. For reasons Defendants have already explained, [Defendants’ Resp. to Private Plaintiffs’ Mot. (Doc. 112) at 17-22], Private Plaintiffs and others similarly situated have not and cannot establish irreparable harm" (22).
For the foregoing reasons, the Court should grant the United States’ motion for a preliminary injunction.
The United States respectfully submits this Statement of Interest under 28 U.S.C. § 5171to advise the Court of the United States’ view that, by denying transgender minors—and only transgender minors—access to medically necessary and appropriate care, SB 613 violates the Equal Protection Clause of the Fourteenth Amendment. Accordingly, Plaintiffs are likely to succeed on the merits of their equal protection claim.
"Intermediate scrutiny is appropriate in this case because discrimination against individuals because they are transgender is a form of discrimination based on sex" (10).
"And neither procedure nor age triggers heightened review. Vacco v. Quill, 521 U.S. 793, 800 (1997); Gregory v. Ashcroft, 501 U.S. 452, 470 (1991). But even if the Plaintiffs could show that the Act distinguishes based on transgender identity or sex, they would still lose. Individuals who identify as transgender do not form a suspect class, so distinguishing based on transgender identity does not trigger heightened review. And any classification centers around biological differences between the sexes, not stereotypes, so SB 613 passes intermediate scrutiny" (11).
"Here, the Court should conclude that SB 613 discriminates on the basis of sex because the medical treatments available to a minor depend on the sex the minor was assigned at birth" (11).
"...SB 613 warrants intermediate scrutiny for the separate and independent reason that it discriminates on the basis of transgender status, a quasi-suspect classification" (13).
"In any event, individuals who identify as transgender do not constitute a suspect class that receives heightened scrutiny. Aside from the obvious—race, sex, national origin, religion, etc.—the Supreme Court rarely designates suspect or quasi-suspect classes. See, e.g., City of Cleburne v. Cleburne Living Ctr., 473 U.S. 432, 442-46 (1985). Indeed, the Court has rejected suspect classification for disability, age, and poverty. Id.; Mass. Bd. of Retirement v. Murgia, 427 U.S. 307, 313 (1976); San Antonio Ind. Sch. Dist. v. Rodriguez, 411 U.S. 1, 28 (1973). The fact that so few classifications rise to the level of 'suspect' itself casts 'grave doubt' on the assertion that transgender identity does. Adams, 57 F.4th at 803 n.5" (16).
"SB 613 penalizes medical practices performed upon a minor 'for the purpose of attempting to affirm the minor’s perception of his or her gender or biological sex, if that perception is inconsistent with the minor’s biological sex.' § 1(A)(2)(a). A transgender person is, by definition, someone whose gender identity is not consistent with their sex assigned at birth" (13).
"SB 613’s ban on medically necessary gender-affirming care for transgender youth cannot survive intermediate scrutiny for two reasons. First, even assuming the State’s asserted interest of protecting youth is genuine, SB 613 is not substantially related to that interest because banning well-established, medically necessary, gender-affirming care is harmful, not beneficial. Second, the stated objective of protecting youth from dangerous treatments does not appear to be fully 'genuine,' see VMI, 518 U.S. at 533, and appears instead to be a 'largely pretextual' justification, see Ladapo, 2023 WL 3833848, at *11, lacking accurate scientific or medical basis" (18).
"Even if this Court believes that SB 613 classifies by sex or that individuals who identify as transgender constitute a suspect class, the Act still does not have an equal-protection problem...But males and females are not similarly situated with respect to receiving sex hormones or obtaining certain surgeries. See supra Section II.A. So a law targeting the unique problems inherent in providing cross-sex hormones or operating on one sex can’t ignore those biological realities" (18).
"Even if lawmakers’ asserted interest of protecting youth were genuine, SB 613’s ban on transgender youth receiving certain forms of medically necessary gender-affirming care is not 'substantially related' to achieving that objective. See VMI, 518 U.S. at 533. Instead, banning these forms of gender-affirming care will have devastating effects on many transgender children while providing no countervailing benefit to them or anyone else" (18-19).
"...if States can prohibit dangerous gender-transition procedures on minors, parents have no independent right to put their preteen on puberty blockers or cross-sex hormones. In sum, parents may have a (qualified) right to decide which lawful medical procedures their children receive; they do not have the right to expand the menu of options" (21).
"SB 613 implicitly acknowledges the longstanding safety of these treatments, as it allows health care providers to prescribe and administer them for purposes other than gender dysphoria" (21).
SB 613 bans certain forms of medically necessary care for transgender minors, while leaving non-transgender minors free to receive the same procedures and treatments. The law fails intermediate scrutiny because banning medically necessary care to treat gender dysphoria is not substantially related to serving an important government objective, and because Oklahoma lawmakers’ asserted purpose—“protecting” minors from certain care—is pretextual. Instead, the law expresses Oklahoma lawmakers’ moral disapproval of transgender people, endangers the health of transgender youth, blocks parents and health care providers from making individual determinations regarding the appropriate care of transgender children, and threatens health care providers with criminal and civil liability, as well as professional licensing sanctions, simply for treating minor transgender patients consistent with broadly accepted standards of medical care. SB 613 violates the Equal Protection Clause of the Fourteenth Amendment, and Plaintiffs are likely to succeed on the merits of their equal protection claim.
Plaintiffs’ motion for a temporary restraining order seeks a temporary pause of a two-subject bill enacted in clear violation of the Nebraska Constitution’s single-subject rule. For three reasons, the government’s response to that motion confirms that a TRO should issue.
"Compound L.B. 574 violates § 14, and is therefore void and unenforceable, because it includes two subjects: an abortion ban and restrictions on gender-affirming care for youth. Compound L.B. 574 thus deprives Plaintiffs of their right to be subjected only to laws adopted in conformity with § 14’s constitutional safeguards" (14).
"Defendants’ primary merits argument is that the abortion ban and the gender-affirming care restrictions in L.B. 574 fit within the subject of 'public health and welfare'" (7).
For the foregoing reasons, and those provided in Plaintiffs’ temporary-injunction brief, the Plaintiffs respectfully urge the Court to issue a temporary injunction and to deny the Defendants’ Motion to Dismiss.
The Act unconstitutionally burdens the rights of transgender minors in Montana to receive critical, medically necessary, and potentially life-saving health care. However, the Act allows the use of the same treatments when provided to minors for the purpose of treating other conditions...Based on these considerations, Plaintiffs are entitled to a preliminary injunction prohibiting Defendants from enforcing the Act, directly or indirectly, against the transgender youth across Montana whose lives hang in the balance.
"'A minor born as a male may be prescribed testosterone . . . but a minor born as a female is not permitted to seek the same medical treatment.' Id. 'Under the challenged statute, is the treatment legal or illegal? To know the answer, one must know the adolescent’s sex. If the adolescent is a natal male, the treatment is legal. If the adolescent is a natal female, the treatment is illegal. This is a line drawn on the basis of sex, plain and simple.' Doe v. Ladapo, No. 4:23cv114-RHMAF, 2023 WL 3833848, at *8 (N.D. Fla. June 6, 2023) (finding Florida’s ban differentiates based on sex)" (19).
"In other words, 'sex plays an unmistakable and impermissible role' in the Act, which 'intentionally penalizes a person . . . for traits or actions that it tolerates' in another individual simply because of sex assigned at birth. See Bostock, 140 S. Ct. at 1741–42" (20).
"Transgender and non-transgender adolescents in Montana seeking health care of the type potentially subject to the Act are similarly situated for equal protection purposes. Both groups seek medically necessary healthcare, including the treatments covered by the Act, when indicated for their medical needs. However, the Act only affects transgender youth seeking gender-affirming medical care to treat their gender dysphoria" (20-21).
"The Act makes it such that transgender adolescents who are eligible for state assistance are unable to access medically necessary treatment, while non-transgender adolescents who are eligible for state assistance can access such treatment" (23).
"The Act specifically bars the provision of a wide range of medical treatments and procedures when, and only when, they are provided to minors for the purpose of treating gender dysphoria" (21).
"First, transgender people, in Montana and elsewhere, have been 'subjected to such a history of purposeful unequal treatment.' In re S.L.M., 287 Mont. at 33, 951 P.2d at 1371" (24).
"Second, transgender people suffer a level of 'political powerlessness' sufficient to warrant 'extraordinary protection' under the law because of the community’s small population size and the enduring societal prejudices against transgender people. In re S.L.M., 287 Mont. at 33, 951 P.2d at 1371" (25).
"The Act does not serve a compelling governmental interest. The Act’s only stated justification 'is to enhance the protection of minors and their families . . . from any form of pressure to receive harmful, experimental puberty blockers and cross-sex hormones and to undergo irreversible, life-altering surgical procedures prior to attaining the age of majority'" (29).
"The Act flatly does not serve any compelling governmental interest, and indeed accomplishes precisely the opposite result. As explained in the expert declarations of Dr. Johanna Olson-Kennedy and Dr. Danielle Moyer, gender-affirming care is medically necessary and effective treatment well-supported by research and experience, and its prohibition will have dire consequences for transgender adolescents" (29).
"First, rather than protecting the health of minors, it gravely threatens the health and well-being of transgender adolescents by denying them access to life-saving care" (31).
"Second, though the legislature claims that medical treatments and procedures used to treat gender dysphoria in minors pose risks to the health of those minors, that argument is completely undermined by allowing those same treatments for cisgender minors with no explanation as to why the care is only safe for the latter group" (31-32).
"The Act’s prohibition against well-accepted medical treatments for adolescents with gender dysphoria infringes on parents’ fundamental rights to make decisions regarding the medical care of their children" (33).
"The Act deprives minors and their parents of the right to seek what every major medical association has recognized is safe, effective, and necessary care, and in so doing it endangers children against their wishes and the wishes of their parents" (33).
"The Act violates patients’ right to privacy by drastically limiting their ability to 'choose . . . medical treatment,' id. ¶ 52, and make necessary and appropriate medical decisions in concert with their parents and provider. The Act also intrudes upon the private relationship between a patient and a health care provider, essentially imposing the State’s ideological opinion on the patient-provider relationship and restricting providers’ ability to rely on their expertise and reasoned medical judgment in recommending and seeking the best health care options for their patients. Only transgender people are subjected to these infringements on their right to privacy when seeking the banned care, and the medical options foreclosed by the Act are often of critical importance to their health and wellbeing" (35).
"...the Act directly violates patients’ right to make medical decisions in concert with their health care providers free from government interference. Act, § 4(1)(c). The Act would deny transgender adolescents the right to elect gender-affirming care, even though it is evidence-based care supported by the consensus of qualified medical professionals in the field" (37).
"The Act violates patients’ right to dignity by threatening and demeaning the humanity and identity of transgender people. A person’s ability to live their life as their true self, consistent with their core identity, and—specifically to the point here—to align their body with their gender identity, is at the heart of the notion of dignity. By drastically limiting the ability of transgender people to seek potentially life-saving care that would allow them to live in alignment with their gender identity, the Act infringes on their fundamental right to dignity. This analysis is subject to strict scrutiny. See Walker, ¶ 74" (38-39).
"The Act infringes on Montana’s constitutional protection of free speech by providing that '[a]ny individual or entity that receives state funds to pay for or subsidize the treatment of minors for psychological conditions, including gender dysphoria, may not use state funds to promote or advocate the medical treatments prohibited in subsection (1)(a) or (1)(b).' Act, § 4(4). That is, the Act bars healthcare professionals from speaking—and their patients and their parents from hearing—about medically accepted treatments for gender dysphoria. The Act is a content and viewpoint-based regulation of speech" (40).
"Such content-based regulation of speech is 'presumptively unconstitutional and may be justified only if the government proves that it is narrowly tailored to serve compelling state interests' under strict scrutiny. NIFLA, 138 S. Ct. at 2371; Reed, 576 U.S. at 163; see also Lamoureux, ¶ 21" (40).
"Plaintiffs have demonstrated that the Act infringes on the constitutional rights of equal protection, parental rights, privacy, health, dignity, and free expression, and have accordingly demonstrated irreparable injuries" (43).
"Second, absent an injunction, transgender youth like the minor Plaintiffs here are at risk of facing the 'severe, ongoing psychological distress and the high risk of . . . suicide' related to gender dysphoria, which unquestionably constitutes irreparable harm. See Edmo, 935 F.3d at 797–98 (holding deprivation of a plaintiff’s constitutional right to adequate medical care causes irreparable harm)" (43).
FOR THESE REASONS, Plaintiffs Scarlet van Garderen, Jessica van Garderen, Ewout van Garderen, Phoebe Cross, Molly Cross, Paul Cross, Jane Doe, John Doe, Dr. Juanita Hodax, and Dr. Katherine Mistretta respectfully request the entry of an order:
Plaintiffs bring this action for declaratory and injunctive relief prohibiting its enforcement. The law by its own terms will not take effect until January 2024. Plaintiffs will work with Defendants’ counsel and the Court to set a schedule for a preliminary injunction motion that will allow the Court to resolve that motion before the law would otherwise take effect.
"The Healthcare Ban prohibits the provision of various medical treatments to minors only when the care is provided 'for the purpose of attempting to alter the appearance of or affirm the child’s perception of the child’s sex if that perception is inconsistent with the child’s biological sex.' HB 71E1 § 1, 18-1506C(3). Whether or not a person can receive certain medical treatments turns on their sex and on whether the care is consistent with stereotypes associated with a person’s sex assigned at birth" (27).
"Discrimination based on transgender status and sex is subject to heightened scrutiny under the Equal Protection Clause and is therefore presumptively unconstitutional, placing a demanding burden of justification upon the State to provide at least an exceedingly persuasive justification for the differential treatment. Transgender people have obvious, immutable, and distinguishing characteristics that define that class as a discrete group. These characteristics bear no relation to transgender people’s abilities to perform in, or contribute to, society. Transgender people have historically been subject to discrimination, and remain a very small minority of the American population that lacks political power" (28).
"Under the Healthcare Ban, the same medical treatments that are prohibited when provided to transgender adolescents to help align their bodies with their gender identity may be provided to cisgender adolescents to help align their bodies with their gender identity, or for any other purpose" (28).
"That fundamental right of parental autonomy includes the right of parents to seek and follow medical advice to protect the health and wellbeing of their minor children. Parents’ fundamental right to seek and follow medical advice is at its apogee when the parents, their minor child, and that child’s doctor all agree on an appropriate course of medical treatment" (30).
"The Healthcare Ban’s prohibition against well-accepted medical treatments for adolescents with gender dysphoria stands directly at odds with parents’ fundamental right to make decisions concerning the care of their children. The Healthcare Ban barges into Idaho families’ living rooms and strips Idaho parents of the right to provide medical care for their children. The Healthcare Ban does nothing to protect the health or wellbeing of minors. To the contrary, it gravely threatens the health and wellbeing of adolescents with gender dysphoria by denying their parents the ability to obtain for them necessary medical care that is recognized as safe and effective by every major medical association in the United States" (30).
"Because the Healthcare Ban is unconstitutional, if it is published in the Idaho Code, it will mislead and deceive Idahoans, including medical professionals, law enforcement, other government actors, and the general public, about the requirements of the law. The publication of HB 71’s provisions in the official Idaho Code, especially without clear notice that the law is unconstitutional and unenforceable, would coerce compliance with the law despite its unconstitutionality and illegality, chill health care providers from providing necessary medical care, chill minors and their parents from seeking necessary medical care, and promote unconstitutional and illegal enforcement of the law by government actors" (31).
Because the Ban is unconstitutional, void, and unenforceable in its entirety, Plaintiffs seek temporary and permanent injunctions to prevent the Ban from taking effect and causing them immediate and irreparable harm.
"...an actual controversy exists between Plaintiffs and Defendants concerning rights and obligations under Texas law, including the Texas Constitution" (61).
"Parents’ fundamental right to seek and to follow medical advice is at its apex when the parents’ and child’s liberty interests in pursuing a course of medical care align, and the child’s medical providers agree and have recommended as appropriate the course of medical treatment. The Ban’s prohibition on providing evidence-based and medically necessary treatment for adolescents with gender dysphoria stands directly at odds with parents’ fundamental right to make decisions concerning the care of their children, particularly when it aligns with the adolescent’s liberty interests and the recommendations of their medical providers. The Ban interferes with Texas families’ private decisions and strips Texas parents, including Parent Plaintiffs and PFLAG parent members, of the right to seek, direct, and provide medical care that their children need" (62).
"The Ban does nothing to protect the health or wellbeing of minors. To the contrary, it gravely threatens the health and wellbeing of adolescents with gender dysphoria by denying their parents, including Parent Plaintiffs and PFLAG parent members, the ability to obtain necessary and often lifesaving medical treatment for their children" (62).
"The Ban violates Physician Plaintiffs’ and GLMA members’ rights under Section 19 because it bans them from providing medically indicated treatment to transgender adolescents according to the generally accepted standard of care to alleviate the patient’s gender dysphoria, puts physicians’ medical licenses in jeopardy if they provide such treatment, and threatens other disciplinary action and penalties under the Texas Medical Practice Act" (63).
"The Ban does not serve a proper legislative purpose; there is no real and substantial connection between a legislative purpose and the language of SB14, and the Ban works an excessive burden on Texas medical providers treating transgender adolescent patients such that relative to the purported purpose of SB14, the Ban is oppressive. Here, the Ban lacks even a rational relationship to any legitimate government interest" (63-64).
"The Ban classifies based on sex on its face. The Ban harms transgender adolescents, including Minor Plaintiffs, Plaintiff PFLAG minor members, and the patients whom Physician Plaintiffs and Plaintiff GLMA members treat, by denying them medically necessary treatment because of their sex assigned at birth" (64).
"The Ban also discriminates against Parent Plaintiffs and Plaintiff PFLAG parent members by denying them the same ability to secure necessary medical treatment for their children that other parents can obtain, and it does so because of their child’s sex assigned at birth. Under the Texas Equal Rights Amendment, government discrimination based on sex is presumptively unconstitutional and subject to strict scrutiny, placing a demanding burden upon the State to show the law is narrowly tailored to serve a compelling government interest. Discrimination on the basis of nonconformity with sex stereotypes, transgender status, gender, gender identity, gender transition, and sex characteristics are all forms of discrimination because of sex" (64-65).
"The Ban classifies based on transgender status on its face. The Ban harms transgender adolescents, including Minor Plaintiffs, Plaintiff PFLAG minor members, and the patients whom Physician Plaintiffs and Plaintiff GLMA members treat, by denying them medically necessary treatment because of their transgender status. The Ban also discriminates against Parent Plaintiffs and Plaintiff PFLAG parents in the exercise of their fundamental right to make decisions concerning the care, custody and control of their children by denying them the same ability to secure necessary medical treatment for their children that other parents can obtain on the basis of their child’s transgender status" (67).
"Under the terms of the Ban, whether a person can receive certain medical treatment turns on whether they are transgender. Discrimination in the exercise of a fundamental right is also presumptively unconstitutional and is subject to strict scrutiny. The Ban unconstitutionally discriminates against Parent Plaintiffs and Plaintiff PFLAG parent members in the exercise of their fundamental right to make decisions concerning the care, custody, and control of their children by prohibiting them from seeking and following medical advice to protect the health and wellbeing of their children solely because their child is transgender" (68).